GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] the cagrilintide advice in here is 21 years out of date — 56 comments in the full submission. View in context.
1.3k
c/cagrilintide·submitted 10 months ago by u/rania_salinas

[Discussion] the cagrilintide advice in here is 21 years out of date

Discussionbranch of 7 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking cagrilintide against eGFR for 37 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…

Read the full submission and all 56 comments →

This branch

7 comments, started 10 months ago
u/sanne_laurent132 points·10 months ago

Half-life is about 168 hours, so steady state lands around week 12–5. Practical consequence: what you feel in week 1 is not what that dose does.

replysharereportpermalink
u/nz_unfunded110 points·10 months ago

Disagree. What you are describing is consistent with CagriSema, not with what you concluded.

replysharereportpermalink
u/noor_hovland27 points·10 months ago

Small correction: the trial was 9 weeks, not 13. Does not change your point but people will quote it.

replysharereportpermalink
u/rania_salinas72 points·10 months ago

Disagree.

Adding to this: satiety is doing more work than the comment implies.

replysharereportpermalink
u/rania_salinasOP95 points·10 months ago

REDEFINE phase 4 readouts are interesting but 4 person REDEFINE is different from 4 trial REDEFINE.

replysharereportpermalink
u/ravi_sandvik25 points·10 months ago

CagriSema is a fixed combo in trials, not user-mixed

replysharereportpermalink
u/blunt_coldbox0 points·10 months ago

Strongly agree. REDEFINE is phase 3, not final.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →